Imaging of cerebral oxygen metabolism is useful for selecting and monitoring therapy, matching patients with interventions, and optimizing outcomes while reducing the incidence of hemorrhagic changes. We aimed to measure oxygen metabolism using magnetic resonance (MR) imaging. Because the magnetic susceptibility of hemoglobin varies with its redox status, the regional oxygen saturation should be measurable by MR imaging. We derived equations based on the blood oxygenation level-dependent (BOLD) theory and evaluated their validity in patients with chronic cerebral ischemia. From changes in BOLD signal, cerebral blood ‰ow (CBF), and cerebral blood volume (CBV) after loading of acetazolamide or breath-holding, we calculated the cerebral metabolic rate of oxygen (CMRO 2 ) pixel by pixel and compared the results to those of positron emission tomography (PET) examination. The correlation coe‹cient between the 2 modalities was between 0.70 and 0.75 in 4 patients, suggesting the applicability of BOLD-contrast MR imaging, but ranged from 0.39 to 0.47 in assessment of oxygen extraction fraction (OEF). BOLD contrast MR imaging tended to overestimate the region of decreased OEF. Some technical challenges remain for improving the sensitivity of delta BOLD, selective measurement of venous blood volume, and shortening of examination time.
Introduction
Hemoglobin normally exists as either oxy-or deoxygemoglobin. Oxyhemoglobin is diamagnetic, whereas deoxyhemoglobin is paramagnetic and causes more inhomogeneity in the local magnetiĉ eld. As a result, relative amounts of oxy-and deoxyhemoglobin can be observed as change in signal intensity on magnetic resonance (MR) imaging. In evaluating the eŠect on MR imaging of hemoglobin saturation in rat brains, Ogawa and associates 1 observed that the increase in gradient echo MR imaging signal intensity at the superior sagittal sinus after CO 2 loading led to increased cerebral blood ‰ow (CBF), which, in turn, apparently left more oxygen in the venous blood. Their method became known as blood oxygenation level-dependent (BOLD) contrast and has been used primarily for functional brain mapping.
Interestingly, a rise in MR signal intensity was also observed when insulin loading induced hypoglycemia, in turn, decreasing brain oxygen consumption and thus leaving more oxygen in the cerebral venous blood. 1 Thus, BOLD contrast can also indicate oxygen metabolism in the brain and allows imaging in vivo. We have used the BOLD technique to map cerebrovascular reserve capacity in patients with chronic ischemia. 2 Davis and colleagues 3 proposed a basic theory for the relationships between cerebral perfusion, cerebral oxygen metabolism, and BOLD signal. Simultaneous measurement of both local cerebral perfusion and BOLD permits calibration of the BOLD signal against known changes in CBF. [4] [5] [6] [7] [8] Assuming a constant in‰uence of CBF change on the BOLD signal and a known relationship between changes in CBF and cerebral blood volume (CBV), 9,10 changes in cerebral metabolic rate of oxygen (CMRO 2 ) during brain stimulation may be estimated noninvasively.
Although those previous papers showed that BOLD measurement may be used to calculate cerebral metabolic rate of oxygen (CMRO 2 ), that use focused only on changes of oxygen metabolism during brain stimulation and was not applied to clinical use for imaging CMRO 2 or evaluation of brain penumbra.
Positron emission tomography (PET) is a reliable method to examine cerebral oxygen metabolism, and PET results give clinically useful information for selecting patients likely to beneˆt from reperfusion therapy and excluding those likely to be harmed. However, PET is not convenient for routine examination nor widely available to general hospitals, so many researchers have tried to apply MR imaging. Several clinical trials have been done to delineate ischemic penumbra either to select patients for thrombolytic treatment or to test whether perfusion-diŠusion mismatch predicts recovery with reperfusion. [11] [12] [13] Unfortunately, practical beneˆts were not clear, and new quantitative techniques were required to assess the predictability of response to reperfusion therapy. Therefore, we have tried to develop a new technique to assess CMRO 2 . The objectives of this study were to establish an algorithm to calculate CMRO 2 according to the BOLD theory and evaluate its validity by comparing the results obtained with those generated by PET.
Methods
Theory for the calculation of CMRO 2 from BOLD Figure 1 shows a diagram of the relationships between oxygen saturation of hemoglobin, blood ‰ow, blood volume, and oxygen consumption in the brain. Arterial blood is almost always saturated with oxygen, but saturation on the venous side varies depending on cerebral blood ‰ow and tissue oxygen consumption or oxygen extraction fraction (OEF). When a region of the brain is stimulated, the CMRO 2 of that region increases, but regional CBF increases relatively more than oxygen consumption. Because arterial oxygen saturation and local arteriolar blood volume as a fraction of cerebral tissue volume are considered to show little change, then changes in regional BOLD signal are attributed primarily to changes in regional oxygen saturation and vascular volume on the venule side. Ogawa and associates 1 represented the relationships of the BOLD signal with oxygen saturation of hemoglobin and venous blood volume using the equations:
where Y is oxygen saturation of venous blood hemoglobin, CBV V is venous blood volume, and b is a parameter of magnetic susceptibility ratio between oxy-and deoxyhemoglobin under the measurement conditions, and this is deˆned by the equation
Because oxygen saturation of hemoglobin can be substituted for deoxyhemoglobin concentration [dHb], Eq. [1] can be converted to:
[ 2 ]
The changes in R 2 * in 2 diŠerent CBF conditions are:
and
where DR 2 * /R 2 * is the relative change in BOLD signal in images obtained employing the gradient echo method (d BOLD).
Assuming that the oxygen saturation of hemoglobin is nearly 100z on the arterial side, the following approximation can be made concerning cerebral oxygen metabolism from Fick's law:
Then, if the venous blood volume is considered to change passively depending on cerebral blood ‰ow, it can be replaced by the CBF, as:
Therefore, Eq. [3] can be converted to:
Because the term of CMRO 2 in Eq. [6] is one if CMRO 2 is unchanged in the 2 conditions, M can be determined from CBF/CBF 0 and DR 2 */R 2 *`0. Therefore, the relative value of CMRO 2 can be determined from the equations:
We assigned a＝0.38, b＝1.5, based on the results of Monte Carlo simulations from Davis and colleagues. 3 Because it is technically di‹cult to measure CBV V , the venous blood volume, we carried out the calculation here by assuming that CBV total 1CBV V . 
Methods for Measurement

Subjects
We selected 6 consecutive patients with suspected chronic ischemic lesions as subjects and obtained their consent after explaining the examination was for research and that rapid bolus injection of an MR contrast medium would be necessary.
Determination of CBF
We used a standard 1.5-tesla MR system (GE, Signa-LX, Milwaukee, WI, USA). We measured CBF using the dynamic susceptibility contrast (DSC) method, in which gadolinium hydrate is injected as a bolus. The imaging conditions were: 4-shot gradient echo echoplanar imaging (EPI); repetition time (TR)/echo time (TE), 285/23; ‰ip angle (FA), 209 ; bandwidth, 69.93; 128×128 matrix; slice thickness, 5 mm; andˆeld of vision (FOV), 22 cm. Because we performed multi-shot imaging, the practical repetition time was 1.462 s. We inserted a 14-or 16-gauge catheter into an elbow vein and injected 10 mL of gadodiamide hydrate over 2 s. CBF was determined using the theoretical equation of Østergaard's group. 14 In this process, we modiˆed the calculation algorithm to correct the partial volume eŠect (PVE) of arterial input function (AIF):
LV ＝r blood ＝1.04 (g/ml). For venous output function (VOF), we set ROI in the superior sagittal sinus.
Determination of BOLD
We determined BOLD before and after administration of acetazolamide employing one-shot gradient echo EPI. Other imaging parameters were: TR/TE, 3,000/50 ms; FA, 209 ; bandwidth, 100 kHz; 128×128 matrix; slice thickness, 5 mm; and FOV, 22 cm. The slices were positioned in the same plane as for the determination of CBF, and average images of 50 shots were prepared. For reasons described later, imaging was also performed using a breath-holding test, which was found to facilitate the observation of d BOLD. The details of the method have been described elsewhere. 2 Imaging parameters were: TR/TE, 3,000/50 ms; FA, 609 ; receiver bandwidth, 100 kHz; FOV, 24 cm; 128× 128 matrix; slice thickness, 5 mm; slice gap, 7 to 10 mm; and imaging time, 5 min 2 s. Breath-holding for 21 or 24 s was performed 3 times, and d BOLD of each matrix was determined.
Measurement of CMRO 2 and OEF by PET
The Research Institute of Shiga Medical Center performed PET studies using the PCT-3600W system (Hitachi Medico, 8 rings, 15 slices) over 5 min involving the continuous inhalation of C 15 O 2 (300 MBq/min) and 15 O 2 (500 MBq/min). Arterial blood was sampled from the radial artery for quantiˆca-tion. CBV was measured by the inhalation of 1.20 GBq of C 15 O 2 . The CMRO 2 and OEF were calculated with the steady-state method and corrected by the CBV. Details of the method are described elsewhere. 15 
Position adjustment
Position adjustment between PET and MR imaging data was carried out using Dr. View (version 5.07; Asahi Kasei Joho Systems, Tokyo, Japan). Parameters of 3-dimensional (3D) imaging of the brain for position adjustment were: TR/TE, 9.3/2 ms; matrix, 256×256; slice thickness, one mm; and slice gap, -0.5 mm (overlapped). Position was adjusted automatically between PET and 3D brain imaging, and PET images were resliced to correspond with the slices of MR imaging.
Our university institutional review board reviewed and approved the study, and we obtained informed consent from all participants and their responsible caregivers in accordance with the Declaration of Helsinki.
Results
Table summarizes the characteristics of the 6 subjects. PET was performed in 4 patients and judged unnecessary in Cases 1 and 2. Case 3 showed no abnormality in CMRO 2 on PET. Cases 4, 5, and 6 showed regional decreases in CMRO 2 . No increase in OEF was noted in any of the 4 patients.
Because there was no contrast in the rCMRO 2 map between the gray and white matter of the brain in Cases 1 to 3, the method was considered inadequate (Fig. 2) . This was because of the poor quality of d BOLD mapping. We assumed that any head motion or shift after moving the scanner table would be a major source of error, and in Cases 4 to 6, imaging was performed without moving the MR table during the interval between BOLD imaging before and after acetazolamide administration (Fig. 3) . The obtained rCMRO 2 maps were well correlated to the results of PET (Fig. 4) .
To obtain d BOLD with better contrast, breathholding was tried. The regional percent changes of BOLD signal were determined by calculating the mean area under the curve of BOLD signal intensity. Subjects were asked to keep their eyes closed and to hold their breath for 24 s after the end of normal expiration; this maneuver was repeated three times. Figure 4 shows the rCMRO 2 map prepared by the recalculated d BOLD (z) obtained as above. Clearer contrast could be seen than with acetazolamide administration.
We set ROIs at 50 sites as shown in PET results indicated that the OEF was maintained in some regions with reduced CMRO 2 , but decreases in OEF were noted in wider areas by BOLD contrast MR imaging than by PET study. The resulting correlation coe‹cients in Cases 3, 4, 5, and 6 were 0.389, 0.468, 0.421, and 0.444.
Discussion
We found that CMRO 2 mapping, which is based on the intrinsic magnetic susceptibility diŠerences between oxy-and deoxyhemoglobin, has potential clinical utility. Though technical aspects remained to be reˆned, the calculated CMRO 2 maps seemed to be reasonably similar to the results from PET. To our knowledge, this study is theˆrst trial of CMRO 2 by MR imaging to map oxygen metabolism in patients. Our results may lead researchers to try the measurement of oxygenation level by MR imaging.
For clinical purposes, one needs to identify and assess regions of abnormal oxygen metabolism or penumbra. The pixel-by-pixel calculations of CMRO 2 in our method show relative values, which in ischemic regions may vary considerably from the normal ranges found in healthy gray or white matter, making oxygen metabolism anomalies especially apparent in false-color images. The time needed for PET or MR imaging mapping is currently too long for use of such tests in the earliest stages of assessment and treatment of acute cases. Thus, we recruited more chronic patients only, and relatively few were available. However, even with a small number of subjects, our study suggested that BOLD analysis can be used to evaluate brain oxygen metabolism and delineate ischemic penumbra either to select patients for thrombolytic treatment or to test whether perfusion-diŠusion mismatch predicts recovery with reperfusion.
Our method presented several technical di‹cul-ties. First, the sensitivity of d BOLD measurement was low. A slight brain shift markedly aŠects d BOLD results. Functional MR imaging removes that source of errors by correcting for positional misalignment and calculating correlation coe‹-cients using a template instead of simple subtraction. We calculated d BOLD by subtracting the mean 50 images before from those after acetazolamide administration, but the quality of the obtained d BOLD images was suboptimal for CMRO 2 mapping. Alternatively, we tried breath-holding instead of acetazolamide loading. However, this is not an established method and depends on the subject's cooperation. Second, it is technically di‹cult to measure regional blood volume in cerebral veins. We assumed that the regional venous blood volume distribution in the brain is similar to that of the total blood volume and could be replaced in calculation by total blood volume, but this assumption may deserve conˆrmation. Finally, there are intrinsic shortcomings in using the DSC method to measure CBF. The high susceptibility eŠects in and around large vessels bearing contrast medium is likely to bias results of CBF and CBV measurements; we used multi-shot EPI to compensate for this, but we are not sure that this compensation was su‹cient.
For the future, the following points should be considered. New approaches to CBF measurement alternative to the DSC method are needed; injection of contrast medium can be troublesome in patients with acute ischemic stroke. Much shorter examination time is desirable, ideallyˆnishing within 5 min, and there is need for a more precise method of assessing venous blood volume. We are interested in the theory reported by Yablonskiy and associates, 16 which combines gradient echo and spin echo methods (gradient echo sampling of spin echo; GESSE) and determines the OEF from the diŠerence in R 2 between the rephase and dephase. A. Shiino et al.
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Higher magneticˆeld strength may be needed to get higher BOLD contrast.
In conclusion, we showed a theory for CMRO 2 mapping using dynamic susceptibility contrast and BOLD contrast methods. Although there are several technical di‹culties, the results of the high corre-
